Breast PD-L1
| 22C3 PharmDx | 28-8 PharmDx | SP142 Assay | SP263 Assay | |
|---|---|---|---|---|
| Atezolizumab | - | - | 1L (≥1% IC) Companion | - |
| Durvalumab | - | - | - | - |
| Nivolumab | - | - | - | - |
| Pembrolizumab | - | - | - | - |
Therapies
1st line advanced or metastatic TNBC – IC* ≥1%
PD-L1 testing: companion
PD-L1 testing: companion
VENTANA PD-L1 (SP142) Assay
- OptiView and Amplification on a VENTANA BenchMark instrument
- TNBC interpretation guide
- SP142 kit insert